Other Hologic Women's Imaging Innovations Featured at NCBC
Other products displayed at this conference will showcase the versatility of Hologic's women's imaging offerings including an Advanced Body Composition Assessment package for the Company's osteoporosis assessment system, and a new tomosynthesis biopsy option for use on the Affirm biopsy guidance system. The tomosynthesis biopsy option is designed to allow radiologists to accurately locate regions of interest for biopsy, even areas visible only on 3D images. Using the tomosynthesis biopsy option, fewer exposures are required to complete a biopsy, compared to a stereotactic procedure, resulting in an overall reduction in radiation dose.
Ad Statistics
Times Displayed: 112786
Times Visited: 6727 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
Hologic's synthesized 2D (C-View) images will also be shown. C-View images are designed to be used in conjunction with 3D images to provide workflow efficiencies and offer a lower dose alternative for patients. Hologic's C-View synthesized 2D image option received CE marking in 2011 and while not yet approved in the U.S., received a favorable vote from an FDA Advisory Panel in October 2012.
About Hologic, Inc.
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products. The Company operates four core business units focused on diagnostics, breast health, GYN surgical and skeletal health. With a comprehensive suite of technologies and a robust research and development program, Hologic is committed to improving lives. The Company is headquartered in Massachusetts. For more information, visit www.hologic.com.
Hologic, Affirm, and C-View are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.
Forward Looking Statement Disclaimer
This News Release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effect of the use of the products can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based.
Back to HCB News
